Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 10/20 | 0.76 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.76 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.69 |
| ▸ | HTR2C | P28335 | 4/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | HTR1D | P28221 | 3/20 | 0.59 |
| ▸ | MPO | P05164 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | HTR1B | P28222 | 2/20 | 0.59 |
| ▸ | HTR7 | P34969 | 2/20 | 0.59 |
| ▸ | HTR6 | P50406 | 2/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 1/20 | 0.59 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30396693 | 0.98 | HTR2A (0.73) | HTR2ATRPM8GPR84HTR2CSLC6A4 | |
| Hydrochloric Acid SCHEMBL2537521 | 0.98 | HTR2A (0.73) | HTR2ATRPM8GPR84HTR2CSLC6A4 | |
| SCHEMBL30724496 | 0.86 | HTR2A (1.00) | HTR2ATRPM8GPR84HTR2CSLC6A4 | |
| SCHEMBL626030 | 0.86 | HTR2A (1.00) | HTR2ATRPM8GPR84HTR2CSLC6A4 | |
| SCHEMBL3280241 | 0.86 | GPR84 (0.73) | HTR2ATRPM8GPR84HTR2CSLC6A4 | |
| Methane SCHEMBL26617454 | 0.85 | HTR2A (0.97) | HTR2ATRPM8GPR84HTR2CSLC6A4 | |
| Hydrochloric Acid SCHEMBL892839 | 0.85 | HTR2A (0.97) | HTR2ATRPM8GPR84HTR2CSLC6A4 | |
| Hydrochloric Acid SCHEMBL686594 | 0.85 | HTR2A (0.97) | HTR2ATRPM8GPR84HTR2CSLC6A4 | |
| SCHEMBL24452687 | 0.83 | GPR84 (0.69) | HTR2ATRPM8GPR84HTR2CSLC6A4 | |
| SCHEMBL3181757 | 0.83 | GPR84 (0.69) | HTR2ATRPM8GPR84HTR2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1519932-B1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LTD (GB) | 2007-10-03 | — | — | EP | claimed |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CYCLACEL LIMITED (GB) | 2005-09-29 | — | — | US | claimed |
| EP-1519932-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | Cyclacel Limited (GB) | 2005-04-06 | — | — | EP | claimed |
| WO-2004005278-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LIMITED (GB) | 2004-01-15 | — | — | WO | claimed |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260071243-A1 | BIOLOGICAL PRODUCTION OF TRYPTOPHAN-DERIVED PRODUCTS | UNIV TEXAS (US) | 2026-03-12 | — | — | US | disclosed |
| EP-3600451-B1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250354108-A1 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | UNIV DANMARKS TEKNISKE (DK) | 2025-11-20 | — | — | US | disclosed |
| US-20250057861-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2025-02-20 | — | — | US | disclosed |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2024-12-12 | — | — | US | disclosed |
| US-12138276-B2 | Halogenated psilocybin derivatives and methods of using | Enveric Biosciences Canada Inc. (CA) | 2024-11-12 | — | — | US | disclosed |
| WO-2004005278-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| US-5332748-A | Antiischemic, antianoxic | ROUSSEL-UCLAF (FR) | 1994-07-26 | — | — | US | disclosed |
| EP-0317427-B1 | Substituted derivatives of 20,21-dinoreburnamenine, process for their preparation and intermediates obtained in this way, their use as medicines, and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1994-01-12 | — | — | EP | disclosed |
| US-5093337-A | SUBSTITUTED DERIVATIVES OF 20,21-DINOREBURNAMENINE, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL UCLAF (FR) | 1992-03-03 | — | — | US | disclosed |
| EP-0317427-A1 | Substituted derivatives of 20,21-dinoreburnamenine, process for their preparation and intermediates obtained in this way, their use as medicines, and pharmaceutical compositions containing them | ROUSSEL-UCLAF (FR) | 1989-05-24 | — | — | EP | disclosed |
| US-4138489-A | FORMALDEHYDE, QUATERNIZATION | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12138276-B2 | Halogenated psilocybin derivatives and methods of using | CES2, MAOB, CNR1 | HTR2A 150/4885TRPM8 3552/4885GPR84 2304/4885 |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MCL1, CD44, CRABP2 | HTR2A 4440/4885TRPM8 3417/4885GPR84 2212/4885 |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MCL1, POU2F1, NES | HTR2A 3307/4885TRPM8 2318/4885GPR84 2628/4885 |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | HTR2A 4440/4885TRPM8 3417/4885GPR84 2212/4885 |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CCNL2, TP53, MDM2 | HTR2A 2487/4885TRPM8 3901/4885GPR84 3943/4885 |
| US-20260071243-A1 | BIOLOGICAL PRODUCTION OF TRYPTOPHAN-DERIVED PRODUCTS | TPH1, TPH2, SLC6A4 | HTR2A 8/4885TRPM8 3842/4885GPR84 1628/4885 |
| US-20250057861-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | CES2, MAOB, CNR1 | HTR2A 150/4885TRPM8 3552/4885GPR84 2304/4885 |
| US-20250354108-A1 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | INMT, KARS1, MIA3 | HTR2A 2339/4885TRPM8 3824/4885GPR84 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.